Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease.
Szu-Ying LinKun-Ju LinPo-Chen LinChin-Chang HuangChiung-Chih ChangYi-Chung LeeIng-Tsung HsiaoTzu-Chen YenWen-Sheng HuangBang-Hung YangPei-Ning WangPublished in: Alzheimer's research & therapy (2019)
Our results demonstrate the possibility of utilizing APOE genotypes in combination with plasma Aβ1-42 levels as a pre-screening tool for predicting the positivity of amyloid PET findings in early stage dementia patients.
Keyphrases
- positron emission tomography
- early stage
- computed tomography
- end stage renal disease
- pet ct
- pet imaging
- newly diagnosed
- cognitive decline
- ejection fraction
- chronic kidney disease
- high resolution
- prognostic factors
- peritoneal dialysis
- high throughput
- squamous cell carcinoma
- type diabetes
- radiation therapy
- metabolic syndrome
- mass spectrometry
- patient reported
- single cell
- photodynamic therapy